Sell Side Advisor

Duff & Phelps Advised Comprehensive Clinical Development on the Sale of its Early Development Division to Actavis, Inc.

In July 2013, Comprehensive Clinical Development (CCD) sold its Early Development Division to Actavis, Inc. (Actavis).   

About Comprehensive Clinical Development
Comprehensive Clinical Development is a clinical research company focusing on clinical pharmacology, central nervous system (CNS) and oncology trials. CCD’s Early Development Division, operating out of a state-of-the-art clinical research facility in Miramar, Florida, has significant expertise in complex Phase I - IIa studies and maintains a sizable database of well-characterized healthy volunteers and disease state special populations.

About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  Actavis has global headquarters in Parsippany, New Jersey and has operations in over 60 countries.

Transaction Role
Duff & Phelps acted as the exclusive financial advisor to CCD in connection with CCD’s §363 sale process pursuant to the U.S. Bankruptcy Code and provided M&A advisory services in connection with the sale of CCD’s Early Development Division to Actavis.



Mergers and Acquisitions (M&A) Advisory

Kroll’s investment banking practice has extensive experience in M&A deal strategy and structuring, capital raising, transaction advisory services and financial sponsor coverage.

Valuation Services

When companies require an objective and independent assessment of value, they look to Kroll.

Corporate Finance and Restructuring

M&A advisory, restructuring and insolvency, debt advisory, strategic alternatives, transaction diligence and independent financial opinions.


Fairness Opinions

#1 ranked provider of fairness opinions for boards of directors and special committees.

Transaction Advisory Services

Kroll’s Transaction Advisory Services platform offers corporate and financial investors with deep accounting and technical expertise, commercial knowledge, industry insight and seamless analytical services throughout the deal continuum.